Biocurious: An effective treatment can often depend not only on the drug itself but also on the method of its delivery.

March 05, 2025 11:00 AM AEDT | By Team Kalkine Media

Biocurious: An effective treatment can often depend not only on the drug itself but also on the method of its delivery. — Image source: shutterstock

Enhancing Drug Administration with Alternative Forms

Gelteq, a company listed on the Nasdaq, has been focusing on improving drug administration for individuals who experience difficulty swallowing solid medications. In collaboration with Monash Medicines Innovation Centre, the company has developed pouch-based gel formulations capable of delivering essential nutrients and therapeutic compounds efficiently. This approach aligns well with the preferences of individuals who regularly use gel-based supplements, such as athletes and fitness enthusiasts.

Advancements in Vaccine Delivery Through Microarray Patches

Vaxxas has been at the forefront of developing microarray patch technology, which offers an alternative to conventional needle-based vaccinations. Through collaborations with organizations such as Merck and funding from agencies like BARDA, this approach aims to enhance vaccine administration by using the skin as a delivery route. By enabling reduced dosage requirements and simplified logistics, this technology holds promise for widespread immunization programs.

Broadening Pharmaceutical Offerings with New Delivery Mechanisms

ASX-listed companies are also introducing novel drug delivery methods. LTR Pharma, trading as ASX:LTP, has developed an oral spray version of traditional medications, providing a rapid onset of action compared to conventional tablets. Wellnex Life (ASX:WNX) has gained approval for liquid paracetamol formulations, offering a more convenient alternative for individuals who prefer liquid-based medications over solid tablets.

Overcoming Challenges in Drug Delivery Innovation

While advancements in drug delivery continue to shape pharmaceutical development, the transition from innovation to market adoption presents significant hurdles. The case of Arovella Therapeutics (ASX:ALA), previously known as Suda, highlights the complexities associated with bringing novel formulations to commercialization. Similarly, Avecho (ASX:AVE), formerly Phosphagenics, has encountered obstacles despite receiving recognition for its technological advancements.

The continuous drive for innovation remains a defining aspect of pharmaceutical research, with companies striving to refine and expand drug delivery methods to enhance therapeutic efficacy and patient convenience.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.